NCT04626505View on ClinicalTrials.gov

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 22, 2020

Primary Completion Date

August 3, 2021

Study Completion Date

September 28, 2021

Conditions
Chronic Kidney DiseaseInflammationCardiovascular Risk
Interventions
DRUG

Ziltivekimab

Administered subcutaneously (s.c., under skin) once every 4 weeks for 12 weeks

DRUG

Placebo (ziltivekimab)

Administered s.c. once every 4 weeks for 12 weeks

Trial Locations (1)

791-0281

Novo Nordisk Investigational Site, Ehime

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
collaborator

Sponsor: Corvidia Therapeutics Inc, a subsidiary of Novo Nordisk A/S

UNKNOWN

lead

Novo Nordisk A/S

INDUSTRY